The "Food and Drug Administration (FDA) has announced approval of tapentadol hydrochloride (Johnson & Johnson), an immediate-release oral tablet for the relief of moderate to severe acute pain." Tapentadol hydrochloride, "for which a trade name has not yet been established, is a centrally acting analgesic that will be available in doses of 50, 75, and 100 mg." The FDA's "approval was based on data from clinical studies involving more than 2,100 patients." Researchers found that the drug "showed significant relief compared with placebo for patients undergoing bunionectomy, a common foot surgery; in pain from end-stage joint disease; and with low back pain or osteoarthritis of the hip or knee."
It appears to have activity at the mu-opiate receptors as well as a norepinephrine reuptake inhibitor.
This medications potency appears to fall somewhere between tramadol and morphine.
As far as I know at the time of writing this post, the DEA has not scheduled it yet.
Interesting information should surface in the coming months to see how safe/effective it is on a very large population.